Both the companies entered into the collaboration in December 2010 under which Phylogica has identified various peptides from its Phylomer libraries that will be further evaluated for their potential as candidate antigens for a vaccine.
Phylogica CEO Paul Watt said the company has identified multiple novel Phylomers that meet the criteria required for further evaluation by Pfizer.
"This provides additional support for the potential value of our Phylomer libraries as a source of novel peptide drug candidates," Watt added.
Phylogica is entitled to an undisclosed milestone payment under the terms of the deal.